

## Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



0 4 APR 2022

FDA ADVISORY No. 20220781

TO

ALL HEALTHCARE PROFESSIONALS AND THE

GENERAL PUBLIC

**SUBJECT** 

Public Health Warning Against the Purchase and Use of the

Counterfeit Drug Product "Carbocisteine (Solmux®) 500 mg

Capsule 100's"

The Food and Drug Administration (FDA) advises the public against the purchase and use of the counterfeit version of the following product:

## **AUTHENTIC**





## COUNTERFEIT





**Counterfeit** – The knurling, security mark and print appearance of the strip are not comparable with the standard features of the registered product.

Figure 1. Comparison between the Authentic and Verified Counterfeit Carbocisteine (Solmux®) 500 mg Capsule 100's (Lot No. U208156)







## AUTHENTIC Carbocisteine **Carbocisteine Solmux** 500 mg Capsule 500 mg Capsule Carbocisteine 100 capsules **Solmux** <sup>®</sup> 500 mg Capsule COUNTERFEIT 100 capsules *Carbocisteine* **Carbocisteine** 500 mg Capsule U208156 HOV 2026 Carbocisteine **Olmux** <sup>©</sup> 500 mg Capsule

Figure 2. Comparison between the Authentic and Verified Counterfeit Carbocisteine (Solmux®) 500 mg Capsule 100's (Lot No. U208156)

Please see patient information learnet for complete.

Keep the product out of reach and sight of children.

STORE AT TEMPERATURES NOT EXCEEDING 30°C. DRHR-717

**Counterfeit** – The print appearance of the box is not comparable with the registered product.

All healthcare professionals and the general public are hereby warned as to the availability of this counterfeit drug product in the market which pose potential danger or injury to consumers. Consumers are also reminded to purchase drug product only from FDA-licensed establishments.

Likewise, all establishments and outlets are hereby warned against selling and/or dispensing of the said counterfeit product with the abovementioned features. The importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009, and Republic Act No. 8203 or the Special Law on Counterfeit Drugs. Anyone found selling the said counterfeit drug product will be penalized.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at <a href="mailto:info@fda.gov.ph">info@fda.gov.ph</a>. To report continuous sale or distribution of unregistered health products, kindly e-mail us via <a href="mailto:ereport@fda.gov.ph">ereport@fda.gov.ph</a>, or through the online reporting facility, <a href="mailto:eReport">eReport</a>, at <a href="mailto:www.fda.gov.ph/ereport</a>. You may also call the Center for Drug Regulation and Research at telephone number (02) 8809-5596. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: <a href="https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH">https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH</a> and fill out all the required fields.

Dissemination of the information to all concerned is requested.

DR. OSCAR G. GUTIERREZ, JR. Officer-in-Charge Director General

DTN: 20220329081543